"The voice for cancer physicians and their patients in Massachusetts."

FDA approves lenalidomide (Revlimid) as maintenance therapy for patients with myeloma

28 Feb 2017 10:30 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved lenalidomide (Revlimid) as maintenance therapy for patients with multiple myeloma following autologous stem cell transplant. Read the full press release

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software